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ABSTRACT  
Brain is considered to be highly impermeable barrier, possessing different obstacles like presence of enzymes, presence of tight junctions that 
limit the entry for most of the drugs. The presence of these obstacles, possess a challenge for administration of the drugs. The conventional 
means of drug delivery in form of emulsions, fail to overcome these obstacles, and hence there is a need for newer drug delivery approach, that 
will cross these barriers of the brain. So, these nanoparticles can be an alternative to other conventional systems. They offer several advantages 
such as improved bioavailability and solubility that are composed of macromolecular materials like lipids and polymers possess low 
cytotoxicity, high drug loading capability, and good scalability these are the most effective colloidal carriers that have the ability to incorporate 
drugs into nanocarriers and used as drug targeting to specific area. Thus, this article will emphasise on properties of Blood Brain Barrier, 
strategies to overcome the blood–brain barrier, literature regarding the use of SLNs in various neurological disease states, production methods 
of SLN and its evaluation. Hence, these solid lipid formulations can be a new form and one of the promising approach for drug  delivery system in 
future, that have remarkable possibility to cross the BBB. 
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INTRODUCTION: 
Brain being one the toughest barrier for the delivery of 
drugs, due to the presence of the blood brain barrier (BBB). 
Delivery of drugs to blood brain barrier has been achieved 
through prodrug approach. Delivery of drugs, through 
nanoparticulates has been a drug delivery of choice, that can 
bypass the RES[ 1-3]. Solid lipid nanoparticles, are specific 
successful nanoparticles, that overcome the limitations and 
toxicity of nanoparticles. These range in nanoscale that has 
the capacity to enclose both hydrophilic and lipophilic drugs 
[4-6]. 
The human brain is divided into 3 main parts on the basis of 
their function and location[7-8] - Fore Brain Mid Brain and 
Hind Brain. Fore Brain is the anterior part of the brain. It is 
responsible for controlling the voluntary actions. It collects 
sensory information from various organs such as ears, skin, 
tongue, eyes. Fore brain has 3 parts namely Cerebrum, 
Thalamus, Limbic system. Cerebrum is considered as biggest 
part of the brain. Higher brain functions such as thinking and 
action are associated with cerebrum. It is divided into 2 
halves called cerebral hemisphere. Right hemisphere related 
to creativity and left hemisphere links to logic abilities. They 
communicate via corpus collosum. Cerebral cortex is outer 
region of cerebrum. cerebral cortex is again divided into four 
lobes Frontal lobe, Parietal lobe, Occipital lobe, Temporal 
lobe functions of cerebrum are sensory processing, 
determines the intelligence of the being, helpful for the 
movement. Thalamus is a small structure which is situated 
within brain. It is located above the brain stem and between 
the cerebral cortex and mid brain. It is responsible for 
carrying the sensory information from body to cerebrum and 
the limbic system. Limbic system is arc shaped structure 
between thalamus and cerebrum. It consists of 
hypothalamus, the hippocampus, the amygdala and other 
nearby areas. It is also known as paleo mammalin cortex. 
Functions of limbic system are management of hunger, fear, 
thirst, anger, and sexual response. 
Mid brain is located below the cerebral cortex and above the 
hind brain. It is also called mesencephalon. Midbrain 
consists of 4 principal regions Tectum, Cerebral aqueduct, 
Tegmentum, Cerebral penducles. It control reflex movement 
of the body and hearing reflexes. 
Hind brain is present at the backside of the brain. It is also 
called as rhombencephalon. Hind brain is connecting link 
between the spinal cord and rest of the brain. It consist of 
Cerebellum, Pons, Medulla oblongata. 
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Figure 1: (a) – The lobes and sulci of cerebrum (b) – The cerebellum and its associated structures. Regenerated from 
source [8] 
 
There is more research going in the areas of brain targeting, 
for treatment of neurological disorders. Most of the economy 
is taken into consideration, for treatment of brain disorders 
like, brain tumour, drugs that will help repair damage, help 
growth of brain cell etc. But these efforts still remain a 
challenge, due to the presence of the obstacles, of the BBB.  
However, obstacles to effective therapy delivery remain, and 
one of the most notable obstacles for drugs to penetrate the 
brain effectively is the BBB[9-10].  
BLOOD BRAIN BARRIER (BBB) 
Basal membrane and brain cells, such as pericytes and 
astrocytes, surrounding the endothelial cells further form 
and maintain an enzymatic and physical barrier known as 
the blood–brain barrier (BBB). 
Structure: 
Although brain capillaries are morphologically similar to 
those found in other tissues, brain vessels are functionally 
bound to the other cells of the brain parenchyma. BBB 
consists of blood vessels built up by specialized endothelial 
cells (ECs), astrocytes, pericytes, and neuronal terminations.  
 
Figure 2:  Blood–brain barrier (BBB) - Regenerated from 
source[8]. 
Astrocytes lay their end-feet over the continuous basal 
lamina and form a very restrictive barrier Pericytes, a type of 
mesenchymal cell, occupy the perivascular space, between 
the capillary wall and astrocytes end-feet, except in the large 
vessels where smooth muscle cells replace them. Pericytes 
play a regulatory role in vasculature tone, stability, 
repairment and angiogenesis as well as they can modulate 
astroglial function. Neurons are also active participants in 
structure of BBB. 
BBB tight junctions are formed between endothelial cells in 
brain capillaries, thus preventing paracellular transport of 
molecules into the brain. Micro-vessels small in diameter and 
thin walls compared to vessels in other organs make up an 
estimated 95% of the total surface area of the BBB, and 
represent the principal route by which chemicals enter the 
brain.. Therefore, only lipid-soluble solutes that can freely 
diffuse through the capillary endothelial membrane may 
passively cross the BBB[11] . 
BLOOD-CEREBROSPINAL FLUID BARRIER (BCSFB) 
BCSFB act as barrier to drugs entering the CNS. It is formed 
by the plexus epithelial cells. The epithelial cells have an 
arrangement in such a manner that it prevents the entry of 
molecules. Due to the presence of inconsistency between the 
interstitial fluid and CSF, put forward the occurrence of CSF-
brain barrier. 
The BBB is constituted of polarized endothelial cells that are 
linked by tight junctions. and presence of these, is 
responsible for low permeability, limiting the drug delivery 
to central nervous system (CNS). Different types of cells like 
pericytes, neurons, astrocytes regulate the BBB 
functionality[12,13].   
Strategies to evade the blood–brain barrier?  
Depending on the properties of BBB, there are number of 
strategies, that include pharmacological line, invasive 
methods and physiological [14-16]. Pharmacological method 
include modification of drug, that will help to cross the BBB. 
But these modifications, affect the biological activity of the 
drug.[17]. While the invasive involves use of techniques as 
interruption of BBB, use of polymers, use of catheters etc. As 
these are invasive, may lead to damage to brain tissues, toxic  
conditions, infection chances. This is not cost effective 
method [18].The physiological way  is considered to be better 
approach as compared to the two methods, as it takes the 
advantage of transport receptors, that help to cross the BBB 
barrier. These all three methods, suffer from the 
disadvantage of limited success rate for treatment of neural 
diseases. Due to the limitations of these methods, research 
has advanced for the use of nanotechnology, for effective 
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delivery of the drugs across the BBB. Nanoparticles have 
played an important role for brain drug delivery [19-20].  
So, in this review, we are focusing on the most promising 
approach of solid lipid nanoparticles for drug brain targeting 
and delivery. 
NOVEL DRUG DELIVERY SYSTEMS FOR BRAIN DRUG 
DELIVERY 
There are numerous colloidal delivery systems tried by many 
investigators to overcome, the barriers of brain. These 
systems include lipid microspheres, microspheres, 
liposomes, niosomes, nanoparticles, and solid lipid 
nanoparticles (SLNs). As per the study of Chen et al. 
polymeric nanoparticles are suitable for drug delivery to the 
brain [21] .As per their study the uptake of the drug by brain 
is through different mechanisms like nanoparticles help in 
opening of the tight junctions, retention of drug in blood 
brain capillaries and transcytosis of these through the 
endothelium. The coating of these polymeric nanoparticles 
by polysorbates help in improvement of bioavailability. The 
mechanism of this includes – the polysorbates help in 
solubilization of lipids and membrane fluidization, Inhibition 
of efflux system, P-gp and endocytosis [22].  But, they possess 
certain limitations as use of organic solvents, polymer 
aggregation, toxic degradation products etc.[23-24]. Though 
nanoparticles have the advantage of crossing the BBB, but 
due to its disadvantages, good alternative to it is SLN. 
SLNs are sub-micron colloidal carriers which are ranging 
from 50 to 1000 nm. SLN introduced in 1991 as an 
alternative to tradition colloidal carriers such as emulsions, 
liposomes and polymeric-micro and nanoparticles. SLN is 
composed of physiological lipid which is dispersed in water 
or aqueous surfactant solution.[25] SLNs are made up of solid 
core with a monolayer phospholipid shell. Protection to 
chemically labile drugs and prolongation of drug release is 
provided by the solid state of the Nanoparticulate matrix.[26].  
 
ADVANTAGES OF SOLID LIPID NANOPARTICLES [27-
28] 
1. Controlled release kinetics can be achieved with solid 
lipid nanoparticles 
2. SLNs improved bioavailability of poorly water soluble 
molecules or protection of drugs which undergoes 
gastro-intestinal degradation 
3. Better stability as compared to liposomes 
4. Lyophilisation is possible 
5. Toxic metabolites are not produced 
6. SLNs are easy to manufacture than bio polymeric 
nanoparticles 
7. No special solvent is required 
8. Both hydrophilic and lipophilic drugs can be 
encapsulated 
DISADVANTAGES OF SOLID LIPID NANOPARTICLES 
1. During storage drug expulsion after polymeric 
transition may occur 
2. Drug loading capacity is poor 
3. Water contents of dispersion are relatively high (70-
99.9%) 
4. Gelating tendency is unpredictable in nature 
5. Growth of particles can occur 
RATIONAL FOR PREPARATION OF SOLID LIPID 
NANO PARTICLES [29] 
1. Use of organic solvent may avoided 
2. Drug stability may increase 
3. Controlled drug release may possible 
4. Drug loading capacity is high 
5. Hydrophilic and lipophilic drug can be incorporate 
Archives regarding the use of SLNs in various 
neurological disease states 
As per the literature, SLNs have the ability of the drug to 
penetrate through the blood-brain barrier (BBB). Abbas et al. 
studied the use of clonazepam for targeting to the brain via 
intranasal olfactory mucosa utilizing nanolipid carriers. 
These were co-loaded with iron oxide nanoparticles 
(SPIONs). These nanolipid carriers were incorporated in situ 
in thermosensitive mucoadhesive gels, that resulted in the 
enhanced delivery of clonazepam[30].. Goppert and Muller 
prepared polysorbate 80 SLNS for brain targeting.  The 
coating of high apoE/apoCII ratio had been absorbed 
absorbed on the particles to achieve brain targeting [31]. As 
per the study conducted by Bhargava s et al, nifedipine 
loaded solid lipid nanoparticles (SLN) were established for 
CNS targeting. The results depicted in-vitro & in-vivo studies 
results showed The Dementia blocking activity on brain cells 
were shown by DNA Fragmentation & Cell Viability studies 
[32].  
In one study, haloperidol (HP)-loaded solid lipid 
nanoparticles (SLNs) were formulated for enhancement of 
HP to brain via intranasal (i.n.) delivery. The highest 
entrapment efficiency (2362.43%) and direct transport 
percentage (95.77%) was found with HP-SLNs as compared 
to the other formulations. Higher DTE (%) and DTP (%) 
suggest that HP-SLNs have better brain targeting efficiency 
as compared to other formulations [33]. In one report, DOX-
SLN were prepared by solvent evaporation method that had 
an average particle size close to 200 nm and polydispersity 
index (PDI) <0.3. The cytotoxicity studies showed the higher 
toxicity of DOX-SLN than plain DOX on U87MG cell lines. The 
cellular uptake studies also confirmed the internalization of 
the DOX-SLN inside brain cancer cells. The study confirmed 
that the development of a SLN as potential carrier for brain 
cancer with enhanced ability to cross the BBB [34].  
As per the study of Morsi N et al, formulated solid lipid 
nanoparticles (SLNs) of Vinpocetine (VIN) for brain targeted 
sustained drug-delivery system.  VIN SLNs were prepared by 
modified high shear homogenization followed by 
ultrasonication technique. The effect of different lipids at 
different concentrations of various surfactants was studied. 
Their Formula (F32) of 5% glyceryl monostearate (GMS) 
with 2% surfactant mixture [Tween 80, Pluronic F 68 (1:1)] 
was the utmost suitable formula for brain delivery having 
EE% of 89.09% ± 1.49, zero-order release kinetics with 
cumulative released percent of 72.12% after 96 h, zeta-
potential of –11.3 ± 0.97 mV. Thus, zero-order sustained 
release profile was achieved and met the requirement for a 
brain targeted . Brain targeted solid lipid nanoparticles for 
brain ischemia: preparation and in vitro characterization [35].  
Wang et al. merged 3', 5'-dioctanoyl-5-fluoro-2'- 
deoxyuridine into the solid lipid nanoparticles. The i.v 
administration of SLN and drug solution was determined and 
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AUC values obtained. The results showed the values obtained 
by SLN were two folds than that by injecting plain drug 
solution [36].  
METHODS OF PREPARATION OF SLN [37]: 
Solvent Emulsification and Evaporation: 
In this method Solid Lipid nanoparticles are prepared by 
precipitation of lipids from emulsions. Lipids are dissolved in 
organic solvents like cyclohexane and then emulsified in 
aqueous phase by high pressure homogenization.   
Nanoparticles dispersion is formed by precipitation of the 
lipid in aqueous medium and evaporation of solvent from 
emulsion under reduced pressure (40-60 mbar). 
Nanoparticles of 25 nm size range are formed by this 
method. 
High Pressure Homogenization: 
Solid lipid nanoparticles can be produced by most reliable 
and powerful High Pressure Homogenization technique. In 
this technique liquid push through narrow gap with high 
pressure (100-2000 bar) using High Pressure Homogenizer. 
The fluid accelerates with very high velocity (1000km/hr) to 
a very short distance. Very high shear stress and cavitation 
forces causes disruption of particles down to submicron 
range. 
a) Hot Homogenization 
In Hot Homogenization lipid is melted above the temperature 
of its melting point and pre-emulsion of drug in melted lipid 
and aqueous phase (hot surfactant mixture) is formed by 
high shear mixing device. Due to higher temperature 
viscosity is decreased and small size particles are formed. 
But High temperature may result into degradation of drug 
and carrier and increased homogenization pressure may lead 
to increase in particle size due increased kinetic energy of 
particles. 
b) Cold Homogenization 
Various problems of hot homogenization like temperature 
induced drug degradation, drug distribution into aqueous 
phase during homogenization can be overcome by cold 
homogenization.   In this technique drug containing lipid 
melt is cooled, the solid lipid ground to lipid micro particles. 
Then presuspension is prepared by dispersing these lipid 
microparticles into cold surfactant solution and then 
homogenized at or below room temperature .due gravitation 
force lipid microparticles directly break into solid lipid 
nanoparticles. 
Microemulsion Based Method 
This method involves dilution of microemulsions. 
Microemulsions are composed of low melting fatty acids (e.g. 
Stearic acid ) , an emulsifier (eg. Polysorbate 20), co-
emulsifiers (e.g. Butanol) and water. This mixture is stirred at 
65-70˚C.The hot microemulsion is dispersed in cold water (2-
3˚C) with stirring. Due to high  temperature gradients rapid 
lipid crystallisation occurs and aggregation is prevented. Due 
to Dilution step lipid contents are lower than HPH based 
formulations. 
Ultrasonic Solvent Emulsification Technique : 
This method involves the dissolution of lipid phase into 
organic solvent such as dichloromethane by heating upto  
50˚C. Aqueous phase containing mixture of surfactant and 
emulsifiers is heated upto same temperature and added to 
organic phase after partial evaporation of dichloromethane 
at 50˚C and with constant sirring. This emulsion produced is 
subjected to sonication for appropriate time and finally 
cooled in ice bath to get solidify lipid nanoparticles. 
Spray Drying Method 
Lipids with melting point > 70˚C are recommended for use in 
spray drying technique. Due to high temperature, shear 
forces and partial melting of particles aggregation may occur. 
By using SLN concentration of 1% in a solution of trehalos in 
water or 20% Trehalose in ethanol-water  mixtures (10/90 
v/v ) best results can be obtained. 
Double Emulsion Method 
Drug and stabilizer are encapsulated to prevent the 
partitioning of drug into external water phase during solvent 
evaporation in external water  phase of w/o/w double 
emulsion. 
Precipitation Method 
This method involves emulsification of aqueous phase and 
glycerides dissolved in organic solvent like chloroform. The 
lipid will precipitated forming nanoparticles after 
evaporation of organic solvent. 
Film – Ultrasound Dispersion 
Lipid and drug are mixed with suitable organic solvent. Thin 
lipid film is formed after decompression, rotation and 
evaporation of organic solvent. Then aqueous solution which 
includes emulsion is added. By using ultrasound with probe 
to diffuser at last, solid lipid nanoparticles are produced. 
EVALUATION PARAMETERS [38]  
In Vitro Drug Release: 
Dialysis tubing: In vitro drug release is greatly explained by 
dialysis tubing .In this method SLN dispersion was placed in 
the previously washed dialysis tubing which can be sealed. 
The dialysis sac then dialyzed against the specific dissolution 
medium at room Tem. Then sample is removed from 
dissolution medium at suitable time period, centrifuged and 
analyzed for particular amount of drug content by using the 
suitable analytical method. 
Reverse dialysis: In this method different type of small 
dialysis sac which may containing dissolution medium are 
placed in the SLN dispersion. then  SLNs are then displaced 
into the medium. 
Franz diffusion cell: In the franz diffusion cell presence of 
the Donor chamber in which the SLN dispersion is placed 
with a cellophane membrane. The dispersion is then 
analyzed against the suitable dissolution medium; then 
sample is removed from dissolution medium at suitable time 
period and analyzed the drug content by using suitable 
method like spectroscopy and HPLC method. 
Ex Vivo for permeability testing 
The rat jejunum (20-30cmdistal from the pyloric sphincter) 
is excised from the rats after scanning the animal used for the 
study. 
Analytical Characterization of SLN 
Particle size and Zeta potential: For the measurement of 
the particle size photon correlation spectroscopy (pcs) and 
laser diffraction (LD) are the most powerful technique for the 
measurement of particle size. This method cover a size range 
from a few nanometer to about few nanometer to about 3 
micron. 
Measurement of crystallinity and lipid modification: 
Lipid crystallization modification may appear due to the 
small size of particle and presence of emulsifier. The DSC and 
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X-ray scattering are widely used to determine the presence of 
lipid. 
Co-existence of additional structure: The magnetic 
resonance technique ,nuclear magnetic resonance(NMR) and 
electron spin resonance (ESR) are mostly used to determine 
dynamic phenomenon and presence of Nano-compartment in 
the colloidal lipid dispersion 
Determination of Incorporated drug: For determination of 
drug content the drug and solid lipid particles are separated 
by ultracentrifugation, centrifugation filtration, or gel 
permeation chromatography. Then drug content can be 
determined by using spectrophotometer, HPLC or Liquid 
Scintillation counting. 
CONCLUSION 
SLN comprise an effective drug delivery to brain. The 
advantages of SLNs like controlled release kinetics, improved 
bioavailability, avoid gastric degradation, physical stability 
and no special solvent required make them a choice for drug 
delivery to the brain .  SLNs thus open new channels for 
delivery of drug to brain like antitubercular, antianxiety, 
antibiotics ,neuroleptics etc. SLN are good formulations as 
targeted drug delivery system.SLN bears the properties of 
good patient compliance and economical for delivery of 
drugs. 
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